In 15 patients with rheumatoid arthritis who were in clinical remission the weekly regimen of methotrexate treatment was changed to fortnightly without a change in dose.
Abstract
In 15 patients with rheumatoid arthritis who were in clinical remission the weekly regimen of methotrexate treatment was changed to fortnightly without a change in dose. A total of 13 patients completed a 12 month trial. No change in clinical or laboratory parameters occurred. There was no change in the use of analgesics or non-steroidal anti-inflammatory drugs and the patients remained in remission. Two patients had to be withdrawn after two and four months respectively because of a flare in disease activity. It is suggested that in most patients with rheumatoid arthritis who are treated with methotrexate and whose disease activity is stable a fortnightly regimen can be permitted without affecting drug efficacy. Low dose pulse methotrexate has been established in the last decade as an effective drug in the treatment of rheumatoid arthritis (RA). Long term studies have demonstrated both its sustained efficacy and its acceptable toxicity profile. '" The drug is usually given weekly and previous experience has shown that when methotrexate is discontinued, even after prolonged treatment, a flare of arthritis activity occurs.' The purpose of this study was to determine whether patients with RA who are treated with methotrexate and who are in remission could be changed from a weekly to a fortnightly treatment regimen similar to the schedule used in gold injections.6 patients had radiographic erosions but none had any signs of extra-articular disease. Table I summarises the clinical characteristics of the patients.
STUDY DESIGN
Patients were evaluated by the same doctor before changing the methotrexate schedule and during the study period. The dose of methotrexate was kept unchanged but the schedule was changed from a weekly oral pulse to a fortnightly one. All patients gave informed consent before entering the study. All patients were seen every four to six weeks for evaluation of toxicity, and laboratory and clinical assessment. Clinical evaluation recorded at the baseline visit and every 3 months thereafter consisted of the duration of morning stiffness, the Ritchie index, mean grip strength, and the doctor's and patient's global assessment of pain and disease activity, which were graded as 1 (severe), 2 (moderate), 3 (mild), and 4 (asymptomatic).
Laboratory tests performed included complete blood counts, serum creatinine, alkaline phosphatase, albumin and transaminase levels, erythrocyte sedimentation rate and C reactive protein levels. The use of NSAIDs and analgesics was carefully monitored at each visit. A precondition for restoring the previous once a week schedule after change of the methotrexate regimen was arthritis flare.
STATISTICAL ANALYSIS
Differences between means were determined using a t test for paired differences; p values of less than 005 were considered to be significant. Patients and methods
PATIENTS
The study group comprised 15 patients with RA, all fulfilling the criteria of the American College of Rheumatology, who were treated with methotrexate. These patients are among the cohort of patients prospectively followed up by the authors to determine the efficacy and toxicity of methotrexate in patients with RA and who were the subjects of a previous report. 7 Patients chosen for this study were those in whom the disease was stable for the six months before the start of the trial (a stable methotrexate weekly dosage, up to four tender joints, no non-steroidal anti-inflammatory drugs (NSAIDs) or steroid adjunct treatment). All Results Thirteen of the 15 patients completed the 12 10 Further controlled studies with a larger group of patients followed up for a longer period are needed to confirm this observation.
